Finance

Lists
LENZ:NASDAQ
Lenz Therapeutics Inc
3,84 $
-0,52%
(-0,020) 1D
3,85 $
+0,26% (+0,0100)
Pre-market
Closed: 30 қыр., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LENZ...
Open
3,90 $
High
3,90 $
Low
3,75 $
Mkt. cap
120,65 млн
Avg. vol.
689,78 м.
Volume
125,00
52-wk high
50,19 $
52-wk low
3,60 $
EPS
-4,08 $
Beta
0,66
Shares outstanding
31,42 млн
No. of employees
152
Open
3,90 $
High
3,90 $
Low
3,75 $
Mkt. cap
120,65 млн
Avg. vol.
689,78 м.
Volume
125,00
52-wk high
50,19 $
52-wk low
3,60 $
EPS
-4,08 $
Beta
0,66
Shares outstanding
31,42 млн
No. of employees
152
News stories
From web sources and news partners
About Lenz Therapeutics Inc
CEO-
Employees152
Founded2013
HeadquartersSolana Beach, Калифорния, Америка Құрама Штаттары
SectorPharmaceutical industry
Websitelenz-tx.com
Analyst ratings
Based on 6 analysts giving stock ratings to LENZ in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LENZ in the last 3 months.
Highest
Current 3,84 $
60,00 $ (+1 462,50%)
Average
24,40 $ (+535,42%)
Lowest
7,00 $ (+82,29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Hold
Downgraded
7,00 $
+82,3%
08/12/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/12/2026
Biren Amin
Piper Sandler
Hold
Maintained
7,00 $
+82,3%
08/12/2026
Yigal Nochomovitz
Citi
Buy
Maintained
10,00 $
+160,4%
08/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
38,00 $
+889,6%
08/12/2026
Stacy Ku
TD Cowen
Buy
Reiterated
60,00 $
+1 462,5%
08/12/2026
Last report
2026 ж. 11 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
-1,02 $ / -1,07 $
+5,10%beat
Revenue / Est. (USD)
5,49 млн / 2,38 млн
+130,76%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
12,50 млн
1,59 млн
1,90 млн
5,49 млн
Cost of goods sold
-
418,00 м.
1,08 млн
280,00 м.
Cost of revenue
-
418,00 м.
1,08 млн
280,00 м.
Research and development expenses
3,79 млн
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,60 млн
39,63 млн
44,96 млн
39,38 млн
Operating expense
31,39 млн
39,63 млн
44,96 млн
39,38 млн
Total operating expenses
31,39 млн
40,05 млн
46,04 млн
39,66 млн
Operating income
-18,89 млн
-38,46 млн
-44,14 млн
-34,17 млн
Other non operating income
-14,00 мың
-417,00 м.
3,00 мың
-13,00 мың
EBT including unusual items
-16,70 млн
-35,89 млн
-41,49 млн
-31,92 млн
EBT excluding unusual items
-16,70 млн
-35,89 млн
-41,49 млн
-31,92 млн
Income tax expense
-
2,00 мың
-
3,00 мың
Effective tax rate
-
-0,01%
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-16,70 млн
-35,90 млн
-41,49 млн
-31,92 млн
Net profit margin
-133,60%
-2 260,45%
-2 182,43%
-581,81%
Earnings per share
-0,59
-1,16
-1,32
-1,02
Interest and investment income
2,20 млн
2,99 млн
2,64 млн
2,27 млн
Interest expense
-
-
-
-
Net interest expenses
2,20 млн
2,99 млн
2,64 млн
2,27 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,76 млн
-38,36 млн
-44,02 млн
-34,06 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары